FDA approves Roche’s Alecensa® (alectinib) as first-line treatment for people with specific type of lung cancer
The FDA has approved the supplemental New Drug Application (sNDA) for Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. The Genentech press release including Important Safety Information is linked here.
ALK-positive NSCLC is often found in younger people, who tend to have more advanced disease at the time of diagnosis. They often have a light or non-smoking history.
On behalf of Genentech
